CQDM/CIHR Collaborative Funding Program in Personalized Medicine to Accelerate Drug Discovery
CQDM and CIHR, with five of its institutes, partner in a new
collaborative funding program in personalized medicine across Canada,
to accelerate drug discovery and drug development. This new initiative was launched at the event BioTransfer2014.
Please click here for the call for proposals.
Complementary to former initiatives in personalized medicine, this new
national program offers public and private partners the opportunity to
work together to develop new cutting-edge technologies, computational
tools and devices which will in turn accelerate R&D in the area of
personalized medicine. To be eligible, research must be performed in
Canada with at least one researcher based at a university or affiliated
research institution or hospital and at least one researcher at a small
and medium-sized enterprise (SME) or not-for-profit organization with
important research activities.
The deadline to submit a letter of intent is June 27, 2014. For more information, please visit CQDM’s Web site for program detaills.
Research agenda
Personalized medicine is developing at a rapid pace which brings new
challenges as well as opportunities to the whole spectrum of therapeutic
development, from basic research to its integration in the drug
discovery process. In an effort to bring solutions which will address
the most urgent needs of biopharmaceutical research, CQDM and CIHR will
fund research projects focused on the invention and development of
next-generation of technologies, computational tools and devices in the
following research areas:
- cancer;
- infection and immunity;
- neurodegeneration affecting cognition.